HCA concern on exchange-related coverage attrition, rising uninsured

HCA beats Q1 2026 estimates, reaffirms 2026 guidance despite volume/weather hit and $600–$900 million exchange EBITDA headwind
Q1 2026 EPS was $7.15 and revenue $19.1B, both beating analyst estimates.
Q1 revenue grew 4.3% YoY; adjusted EBITDA up ~2% and adjusted EPS up ~11%.
Patient volumes were weaker than expected, with sharp declines in respiratory-related admissions and ER visits.
Volumes were soft in January from mild respiratory season and winter storms, but rebounded by March.
Respiratory and weather factors cut EBITDA by ~$180 million, viewed as temporary rather than structural.
Medicaid supplemental programs added ~$200 million incremental EBITDA YoY, $120 million above expectations, helping offset softness in patient volumes.
2026 guidance reaffirmed; volume outlook of 2–3% growth maintained despite Q1 shortfall.
Expected 2026 net benefit from Medicaid supplementals now a $50–$250 million YoY decline.
Exchange disruption and payer-mix shifts drove ~$150 million Q1 EBITDA hit, with full-year impact still pegged at $600–$900 million.
Same-facility exchange admissions fell ~15%, while uninsured admissions rose ~16% YoY.
Resiliency and AI-driven efficiency program tracking toward $400 million 2026 cost savings target.
Capital deployment remained aggressive: $1.1B capex, $1.57B buybacks, $183M dividends, leverage conservative.
Board declared a $0.78 quarterly dividend following release of first-quarter 2026 financial results.
Main concern: Exchange-related coverage attrition and rising uninsured/bad debt could pressure earnings and cash collections through 2026.
Mixed quarter, driven by temporary volume/weather headwinds offset by stronger Medicaid supplemental payments and cost controls.
https://finviz.com/quote.ashx?t=HCA&p=d